XTL Biopharmaceuticals Ltd.
XTLB
Rank in Stocks
#30954
XTL Biopharmaceuticals Ltd. is a biopharmaceutical firm dedicated to sourcing... XTL Biopharmaceuticals Ltd. is a biopharmaceutical firm dedicated to sourcing and advancing medicinal products aimed at treating autoimmune conditions. Its principal experimental compound, hCDR1, is primed for Phase II clinical studies, addressing systemic lupus erythematosus and Sjogren's syndrome. The company operates under a licensing agreement with Yeda Research and Development Company Limited, granting it rights for the research, development, and commercialization of hCDR1 across numerous therapeutic applications. Originally incorporated in 1993 as Xenograft Technologies Ltd., the entity rebranded as XTL Biopharmaceuticals Ltd. in July 1995 and is currently headquartered in Ramat Gan, Israel.
Share Price
$1.53
Last synced: 2026-11-09
Market Cap
$4.05M
Change (1 day)
-1.28%
Change (1 year)
-61.36%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade XTL Biopharmaceuticals Ltd. (XTLB)
Category
Healthcare
EPS for XTL Biopharmaceuticals Ltd. (XTLB)
EPS as of December 2024 TTM: $-2.88
According to XTL Biopharmaceuticals Ltd.'s latest financial reports, its current EPS (TTM) is $-2.88. At the end of 2025 the company had an EPS of $-17.00, a decrease compared to its 2024 EPS of $-2.40.
EPS history for XTL Biopharmaceuticals Ltd. from 2001 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-2.88 | -83.06% |
| 2025 | $-17.00 | 608.33% |
| 2024 | $-2.40 | -92.00% |
| 2023 | $-30.00 | 650.00% |
| 2022 | $-4.00 | -412.50% |
| 2021 | $1.28 | -114.04% |
| 2020 | $-9.12 | 119.23% |
| 2019 | $-4.16 | -144.83% |
| 2018 | $9.28 | -441.18% |
| 2017 | $-2.72 | -81.72% |
| 2016 | $-14.88 | -42.94% |
| 2015 | $-26.08 | 49.54% |
| 2014 | $-17.44 | -1.80% |
| 2013 | $-17.76 | 73.44% |
| 2012 | $-10.24 | 8.47% |
| 2011 | $-9.44 | -46.85% |
| 2010 | $-17.76 | -176.55% |
| 2009 | $23.20 | -127.88% |
| 2008 | $-83.20 | -90.55% |
| 2007 | $-880.00 | 44.74% |
| 2006 | $-608.00 | -7.32% |
| 2005 | $-656.00 | -32.79% |
| 2004 | $-976.00 | -4.69% |
| 2003 | $-1.02K | -16.88% |
| 2002 | $-1.23K | 35.09% |
| 2001 | $-912.00 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -643.75% |
US
|
|
| $-7.07 | 145.49% |
US
|
|
| $-5.29 | 83.68% |
AU
|
|
| $12.88 | -547.23% |
BE
|
|
| $21.56 | -848.61% |
NL
|
Questions about XTL Biopharmaceuticals Ltd.'s earnings per share (EPS)
What is XTL Biopharmaceuticals Ltd.'s earnings per share (EPS)?
XTL Biopharmaceuticals Ltd.'s earnings per share (EPS) over the last twelve months is $-2.88, as of Dec 2024.
What was XTL Biopharmaceuticals Ltd.'s earnings per share (EPS) in 2025?
In 2025, XTL Biopharmaceuticals Ltd.'s earnings per share (EPS) was $-17.00, compared with $-2.40 in 2024.
How has XTL Biopharmaceuticals Ltd.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, XTL Biopharmaceuticals Ltd.'s earnings per share (EPS) was highest in 2021 ($1.28) and lowest in 2023 ($-30.00).
How does XTL Biopharmaceuticals Ltd.'s earnings per share (EPS) compare with similar companies?
XTL Biopharmaceuticals Ltd.'s earnings per share (EPS) ($-2.88) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.